Letter to the editorOrgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: Role of adjunctive plasmapheresis
References (3)
- et al.
Heparin-induced thrombocytopenia
J Cardiothorac Vasc Anesth
(1996)
Cited by (16)
A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis
2010, Thrombosis ResearchCitation Excerpt :Danaparoid displaces heparin from its interactions with PF-4 and platelets [9,10] and is currently highly recommended [11] for the treatment of HIT. Although no antidote is available (plasmapheresis can reduce blood loss [12,13 (D Böcker data on file)] danaparoid has a favourable efficacy/safety profile [14] in clinical practice. Patients undergoing haemodialysis (HD) who need an anticoagulant to prevent circuit clotting and systemic thrombosis usually receive unfractionated (UFH) or a low-molecular weight heparin (LMWH).
Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia
2001, Annals of Thoracic SurgeryCitation Excerpt :In this review, the anticoagulant effect of danaparoid sodium during CPB was found to be effective, but with postoperative blood losses larger than those usually observed with heparin. Furthermore, several other case reports described the use of this anticoagulant during CPB [15–19](Table 3). Unfortunately, two major pharmacological properties limit the use of this drug during CPB: the first one is the lack of a specific antidote, the second is its prolonged anti-Xa activity (25 hours approximately) [20].
Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis
2000, Annals of Thoracic SurgeryA Historical Perspective on the Reversal of Anticoagulants
2022, Seminars in Thrombosis and HemostasisGuideline on the management of bleeding in patients on antithrombotic agents
2013, British Journal of Haematology